{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Amarenco P"],"funding":["French Government","SOS-ATTAQUE CEREBRALE ASSOCIATION","Pfizer","AstraZeneca","Merck"],"pagination":["271-280"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6960693"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["4(3)"],"pubmed_abstract":["<h4>Background</h4>In patients with non-cardio-embolic stroke, atorvastatin 80 mg/day reduced the relative risk of recurrent stroke by 16%, and a post hoc analysis showed that achieving an LDL-c of less than 70 mg/dL reduced the relative risk by 28% as compared to an on-treatment LDL of 100 mg/dL or more. Current guidelines from the French drug agency recommend treating with a statin after an ischaemic stroke to a target of less than 100 mg/dL, but no study directly tested LDL-c targets. The Treat Stroke to Target (TST) trial will compare the efficacy of achieving an LDL-c of less than 70 mg/dL versus an achieved LDL-c of 100 ± 10 mg/dL for secondary prevention in patients with recent ischaemic stroke of atherosclerotic origin.Main hypothesis: An achieved on-treatment LDL-c of less than 70"],"journal":["European stroke journal"],"pubmed_title":["Treat stroke to target trial design: First trial comparing two LDL targets in patients with atherothrombotic strokes."],"pmcid":["PMC6960693"],"funding_grant_id":["AOM0900 &amp; AOM10281"],"pubmed_authors":["Steg PG","Touboul PJ","Yelles N","Labreuche J","Vicaut E","Giroud M","Bruckert E","Simon T","Kim JS","Nighoghossian N","Mahagne MH","Amarenco P","Lee BC"],"additional_accession":[]},"is_claimable":false,"name":"Treat stroke to target trial design: First trial comparing two LDL targets in patients with atherothrombotic strokes.","description":"<h4>Background</h4>In patients with non-cardio-embolic stroke, atorvastatin 80 mg/day reduced the relative risk of recurrent stroke by 16%, and a post hoc analysis showed that achieving an LDL-c of less than 70 mg/dL reduced the relative risk by 28% as compared to an on-treatment LDL of 100 mg/dL or more. Current guidelines from the French drug agency recommend treating with a statin after an ischaemic stroke to a target of less than 100 mg/dL, but no study directly tested LDL-c targets. The Treat Stroke to Target (TST) trial will compare the efficacy of achieving an LDL-c of less than 70 mg/dL versus an achieved LDL-c of 100 ± 10 mg/dL for secondary prevention in patients with recent ischaemic stroke of atherosclerotic origin.Main hypothesis: An achieved on-treatment LDL-c of less than 70","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Sep","modification":"2025-04-26T06:15:35.144Z","creation":"2020-05-22T08:32:35Z"},"accession":"S-EPMC6960693","cross_references":{"pubmed":["31984235"],"doi":["10.1177/2396987319838100"]}}